Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Advanced Accelerator Applications
Exelixis
Sanofi
Corcept Therapeutics
Grupo Espanol de Tumores Neuroendocrinos
Novartis
Novartis
University of California, Los Angeles
Montefiore Medical Center
Radiomedix, Inc.
Ipsen
Ipsen
Ipsen
Advanced Accelerator Applications
Novartis
Novartis
Philipps University Marburg
AstraZeneca
Amgen
Novartis
Collaborative Group for Adrenocortical Carcinoma Treatment
Novartis
Corcept Therapeutics
Corcept Therapeutics
INSYS Therapeutics Inc
Corcept Therapeutics
Yale University